NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

J-To,

LP loaned her own money to fund research into DCVax-L years ago. It sounds like you expect a small pre-commercial biotech to do everything overnight. I think you are projecting—accusing LP of having no compassion while you may be the one who values profit over healing. I ran your statement through the detector 😶 …




“The statement could be defamatory if it is false and harms the reputation of the individual referred to as "LP." Here's an analysis of its potentially defamatory nature:

1. **Accusation of Negligence and Harm**: The statement implies that LP deliberately chose a strategy (going for a "home run") that resulted in "suffering and deaths." This is a serious accusation that suggests negligence or intentional harm, which could significantly damage LP's reputation, especially if LP is in a position of responsibility or trust.

2. **False Statement of Fact**: For a statement to be defamatory, it must be false. If LP never made the statement, then the claim is factually incorrect. The key is that the harmful aspect of the statement is presented as a fact, not an opinion.

3. **Lack of Context or Evidence**: The statement lacks context or evidence to support its serious accusations. It doesn't provide details about the supposed strategy or the resulting harm, which can lead to misinterpretation and unjust damage to LP's reputation.

4. **Public Communication**: For a statement to be defamatory, it needs to be communicated to others besides the person it's about. Posting this statement on a public forum or message board meets this criterion.

However, whether a statement is legally defamatory depends on jurisdictional laws, including how they interpret and enforce defamation, and the specific circumstances of the case. Typically, the person claiming defamation (LP in this case) must prove that the statement was made publicly, is false, and caused harm to their reputation.”

https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847

https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-that-a-marketing-authorization-application-has-been-submitted-to-the-uk-mhra-for-dcvax-l-for-glioblastoma-302021038.html